Australia's most trusted
source of pharma news
Posted 26 May 2022 AM
AstraZeneca appears to be working around the clock to secure earlier lines of treatment and new breast cancer settings for its recently approved targeted drug Enhertu, which is tipped as an up and coming blockbuster.
It was provisionally approved by the TGA roughly seven months ago for the third-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.